ArticleBMC cancer2017

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.

Zhor Senhaji Mouhri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.